SAKAR HEALTHCARE LIMITED

Sakar Healthcare Limited reported on its Q1 FY27 earnings during the analyst call held on July 29, 2026. Management highlighted a strong operational and financial performance, with revenue from operations reaching INR 7,297 lakhs, a year-on-year growth of 38%. EBITDA increased by 67% to INR 2,125 lakhs, and profit after tax grew by 120% to INR 1,028 lakhs. The company emphasized its focus on building a robust oncology business, having executed over 65 oncology product contracts and submitted 261 oncology dossiers globally. Management noted the importance of market access and reported 16 marketing authorizations received during the quarter. The integrated EU-GMP approved oncology facility at Bavla is central to their export strategy, with potential revenues projected between INR 800 crores to INR 1,000 crores at optimal utilization over the next 4 to 5 years. Management expressed confidence in the growth of their oncology exports and the overall business.

Management emphasized strong growth and operational progress in the oncology segment.